



Financial Report

2021/2022



HERE FOR LIFE



Protecting life's
moments, for life

If you need to talk about cancer call **13 11 20**

Contents

2021/22 highlights	4
Our performance over time	6
Where the money comes from	8
How we put the money to work	9
Directors' report	10
Auditor's declaration of independence	16
Statement of profit or loss and other comprehensive income	17
Statement of financial position	18
Statement of changes in equity	19
Statement of cash flows	20
Notes to the financial statements	21
Directors' declaration	31
Declaration by Chief Executive Officer in respect of fundraising appeals	32
Independent auditor's report	33

2021/22 highlights

Here is a snapshot of what our supporters helped achieve in 2021/22:



INCREASING CANCER SURVIVAL

In 2021/22, we invested **\$18.2** million in world-class research, funding:



207
researchers



57
projects



25
institutions

In 2021/22, we awarded funding for **12 ground-breaking projects** paving the way for new and more effective cancer treatments. These included projects testing new dual treatments for aggressive childhood brain cancers; investigating how to use artificial intelligence to enhance radiotherapy; and understanding why immunotherapies are effective against some cancers, but not others.

New findings by our researchers at The Daffodil Centre* shows that **4.56 million Australians will be diagnosed with cancer** over the 25-year period from 2020–2044. Although 1.45 million Australians are expected to die, the overall rate of deaths between now and 2044 is projected to fall by around 20%. The study provides a blueprint for how cancer should be controlled and treated into the future. It also allows for future cancer control policy and research to be prioritised according to where the highest burden is expected.

From 1 July 2022, cervical screening by self-collection became a universal option all for people eligible for cervical screening. This major change to the National Cervical Screening Program was directly informed by our research that showed offering self-collection would be an effective approach to **further reduce cervical cancer incidence** by helping to reach more eligible people who are not currently participating in screening.

*The Daffodil Centre is a joint venture of Cancer Council NSW and the University of Sydney.



REDUCING CANCER RISK

205 golf clubs participated in **Improve your long game** in 2021/22, protecting golfers from harmful UV radiation exposure.

People were inspired to create healthy recipes for the whole family by visiting the **Healthy Lunch Box** website **266,449 times**. This is an increase of **29%** from the previous year.



IMPROVING THE QUALITY OF LIFE OF PEOPLE AFFECTED BY CANCER

2,830 people who were struggling with the high cost of cancer received **\$977,700** worth of financial assistance payments.

Our 13 11 20 Information and Support team received **8,797** calls and emails from people affected by cancer, health professionals and the general public.

Our Transport to Treatment drivers made **18,620** trips, so cancer patients and carers could get to life-saving treatment.

We provided **11,569** nights of affordable accommodation to cancer patients and carers, so they could stay close to their treatment centres.



IMPROVING CANCER OUTCOMES FOR PRIORITY POPULATIONS

Throughout 2021/22, our community-facing teams held **73** community events across NSW to improve understanding and access to bowel, breast and cervical screening, reaching over **4600** people.

As part of our commitment to improving screening participation in priority populations, we endorsed a strategy to **support the elimination of cervical cancer** in NSW through targeted interventions for under-screened populations, engagement with Primary Health Networks and a social media and marketing campaign.

We achieved **69 out of 71 deliverables** for our Reconciliation Action Plan, including:


- Developing a suite of culturally appropriate collateral for teams to use at events that resonates with the community
 - Expanding our Aboriginal and Torres Strait Islander cultural education, by launching an eLearn framework for all employees to complete.
-

Our performance over time

Growing investment in research

This year we enabled \$18.2 million of world-class cancer research through The Daffodil Centre – a joint venture between Cancer Council NSW and the University of Sydney – and continued to fund external research projects.

Total research expenditure*



Total research grants funded



*Includes research we fund and conduct. **The reduction in research expenditure in FY20/21 mostly reflects COVID-related deferrals of grant payments and a tail-off in payments for some older grant types.

We also partnered with government and collaborators, seeking competitive grant and contract funding.



	2018	2019	2020	2021	2022
Number of research grants received	13	21	19	31	28
Total research grants received (\$m)	1.9	2.3	2.3	4.4	4.3

Supporting people with cancer

Thanks to our **incredible volunteers and staff members**, we made sure cancer patients could get to their life-saving treatment.

Number of trips by our Transport to Treatment service



2018	2019	2020	2021	2022
22,138	28,407	19,070	20,833*	18,620*

*This year, we continued to see a lower number of Transport to Treatment trips due to the COVID-19 pandemic, which forced the temporary closure of some services, the introduction of capacity limits which reduced our ability to transport patients, and saw some patients delay their treatment or opt for virtual appointments

Number of accommodation nights



2018	2019	2020	2021	2022
21,074	23,144	23,816	17,797*	13,276*

*The reduction in the number of accommodation nights reflects a change in the way we measure and report on data for this service, as well as the ongoing implications of COVID-19 reducing the total number of people receiving treatment.

Financial assistance payments (\$)



COVID-19 meant that people affected by cancer faced additional financial hardship and our Financial Assistance Program continued to support cancer patients and carers with the cost of everyday expenses during this time.

2018	2019	2020	2021	2022
943,000	1,013,258	1,021,325	1,020,805	977,700

We are **providing reliable information** about specific types of cancer, treatments and emotional and practical issues.

Our podcasts, *The Thing About Cancer*, *The Thing About Advanced Cancer* and *Finding Calm During Cancer*, provide easy to understand information for patients and their carers. Cancer-related fatigue, brain fog and feeling unwell can make reading a challenge, but listening to a podcast takes very little effort and can be done at a time and place that suits the listener.

Individual listens



2018	2019	2020	2021	2022
16,451	13,194	23,243*	17,939	29,956*

*We saw a large spike in listens in 2020 due to a new series launch and associated promotion resulting in an overall drop for 2020/21. This year, listens have spiked again due to the launch of an additional Cancer Council podcast series called *Finding Calm During Cancer* and improved website functionality.

Understanding Cancer books and fact sheets distributed in print and digital formats



2018	2019	2020	2021	2022
192,147	179,813	146,878*	119,481*	143,303*

*We distributed fewer *Understanding Cancer* resources in hospitals, treatment centres and regional offices due to COVID-19.

Professional organisations generously volunteer their time and expertise to support cancer patients and carers with legal, financial and workplace issues through Cancer Council's Pro Bono program.

Number of legal, financial and workplace issues



2018	2019	2020	2021	2022
3,719	4,003	3,508	2,942*	2,646*

*We have seen a decrease in referrals since 2020 due to COVID-19, as clients were not attending treatment centres as often for a referral to a health professional. FY21/22 saw the biggest decrease in referral numbers, coinciding with the most widespread lockdowns across the country. This decline was experienced across Australia and we are hopeful referral numbers will increase over FY22/23.

We are so grateful to our generous supporters who continue to fundraise and donate to us as we emerge into the post-pandemic world.

Total fundraising income



	2018	2019	2020	2021	2022
Total fundraising income (\$m)	56.5	63.8	48.1	58.9	53.8
Number of people who left us a Gift in their Will	108	147	134	131	78*

*We are grateful for the generosity of the 78 people who left a Gift in their Will this year. These incredible legacies will make a difference to the future of cancer.

We are working to **prevent** cancer by creating healthier environments and empowering people to reduce their cancer risk.

Improve your long game is our free sun protection program in NSW golf clubs. In NSW, men aged 40+ are 1.5 times more likely to be diagnosed with melanoma and 2.5 times more likely to die from melanoma than women of the same age. *Improve your long game* is a way to engage this often difficult to reach group.

Number of golf clubs participating in *Improve your long game* to reduce the risk of skin cancer for their golfers




2018	2019	2020	2021	2022
111	108	183	198	205

Improve your long game started as a pilot in 2014/15 in just 12 golf clubs on the mid-north coast of NSW. After securing funding from Cancer Institute NSW based on the pilot's success, the program's reach has increased each year.

Thanks to our community's support, we are here to help everyone affected by cancer when they need it most.


Where the money comes from



	2018		2019		2020		2021		2022	
	\$m	%	\$m	%	\$m	%	\$m	%	\$m	%
Gifts in Wills	12.3		17.5		9.6		20.7		14.0	
Regular giving, appeals and donations	20.6		20.9		19.8		18.6		18.1	
Campaigns	20.3		22.5		15.1		16.3		13.2	
Philanthropy	3.3		2.9		3.6		2.7		8.4	
Total fundraising	56.5	77%	63.8	78%	48.1	72%	58.3	72%	53.7	69%
Sale of sun protection products (retail)	7.7	10%	7.6	10%	5.8	9%	5.2	6%	5.2	7%
Investments	4.5	6%	5.1	6%	4.0	6%	6.0	8%	11.1	14%
Grants	2.8	4%	3.4	4%	6.9	10%	10.6	13%	6.8	9%
Other income	1.9	3%	1.7	2%	1.8	3%	1.1	1%	1.0	1%
Total income*	73.4		81.6		66.6		81.2		77.8	

*Excludes capital gains on investments

How we put the money to work



	2018		2019		2020		2021		2022	
Mission expenditure	\$m	%	\$m	%	\$m	%	\$m	%	\$m	%
Research	18.7		19.0		19.8		16.8		18.2	
Community engagement	12.3		10.6		9.1		9.1		8.8	
Advocacy and cancer prevention	4.8		4.4		4.5		4.0		5.6	
Cancer information and support	7.8		10.2		9.0		8.2		9.3	
Sale of sun protection products (retail)	7.2		7.2		5.9		4.9		5.0	
Direct mission support	2.0		0.8		1.8		1.5		2.4	
Total mission	52.8	64%	52.2	64%	50.1	66%	44.5	65%	49.4	66%
Mission enabling expenditure	\$m	%	\$m	%	\$m	%	\$m	%	\$m	%
Fundraising	26.6	32%	26.0	32%	23.4	31%	21.7	31%	23.1	31%
Administration*	3.8	4%	3.5	4%	2.7	3%	2.4	4%	2.1	3%
Total expenditure**	83.2		81.7		76.2		68.6		74.6	

*Items from these categories which are directly related to mission have been reallocated to Direct mission support

**Excludes capital losses on investments

2017 and 2018 reflects administration costs allocated to mission and fundraising on a different basis

Directors' report

For the year ended 30 June 2022

The Directors of Cancer Council NSW (CCNSW) present their report with respect to the results for the financial year ended 30 June 2022 and the state of CCNSW's affairs at that date.

Board of Directors

CCNSW's Constitution provides that the Board directs the affairs of CCNSW. In carrying out its responsibilities and exercising its powers, the Board recognises its overriding responsibility to act honestly, fairly and diligently, and in accordance with the law in serving the interests of CCNSW, including its members, volunteers, supporters, employees and the community.

The following persons were Directors of CCNSW at any time during or since the end of the financial year:

- Nicholas Adams
- Michael Barton
- James Butler
- Nerida Dean
- Haryana Dhillon
- Peeyush Gupta (part)
- Carolyn Heise
- John Laker (Chair)
- Jo Mitchell
- Michael Morgan
- Mark Phillips (part)

About Cancer Council NSW

CCNSW is a member of a national federation of Cancer Councils that covers every state and territory across Australia. Cancer Council believes in a cancer free future and is the only charity in Australia that works across every cancer. While collaborating nationally on issues that impact all Australians, together with its volunteers, supporters, stakeholders, and employees, CCNSW is focused on opportunities, needs and initiatives of importance to NSW.

As the largest cancer charity in Australia, CCNSW is committed to reducing the impact of cancer by reducing cancer risk, increasing cancer survival, improving the quality of life for people affected by cancer, and improving cancer outcomes.

Principal activities during the year and how they assisted in achieving our objectives

The principal activities of CCNSW during the year were aimed at achieving its short and long-term outcomes in the following focus areas:

- research
- prevention
- information and support
- advocacy
- fundraising
- working with the NSW community
- our people

We provide more detail on our activities and achievements in the financial year on pages 4-7 in this document.

How we measure performance, including key performance indicators

We assess the outcome of our work in relation to:

- the prevalence of adverse cancer risks and healthy behaviours
- the unmet needs of cancer patients
- the support of community and government leaders for our agenda in cancer control
- the quality and impact of results from research, and
- trends in net returns from revenue programs.

The operational effectiveness of our work is measured by:

- the coverage of target populations or settings with programs in cancer prevention and support
- mission expenditure ratios to ensure expenditure on mission delivery is maximised
- net income from fundraising and revenue streams
- fundraising cost to income ratios
- the number of NSW people engaged as donors, volunteers, advocates and research participants, and
- the match between the distribution of research funding and the burden of disease and cancer in NSW.

Our key performance indicators and our results for the past five years are outlined in pages 6–7 of this document. Data is captured and reported regularly to provide insight into performance and outcomes. CCNSW conducts regular business reviews and uses its internal auditors to review and advise on the performance of various programs and to identify opportunities for improvements. Annual performance planning is conducted for all staff to ensure alignment with the organisation's direction.

Information on our Directors

Nicholas Adams

BCom (Marketing)

*Chair of the Fundraising and Marketing Committee,
Member of the IT Steering Committee*

Elected to the Board in December 2015, re-elected in December 2018, and re-elected in December 2021.

Mr Adams is a leading Australian marketer and has 23 years' experience in financial services and telecommunications marketing with companies such as Allianz, Telstra, Westpac, and American Express.

As a marketing leader, he has expertise in customer relationship management (CRM), loyalty and digital marketing, and building data-driven marketing programs to drive both revenue and customer engagement with brands.

Professor Michael Barton OAM

MBBS, MD, FRANZCR

Member of the Cancer Research Committee

Appointed to the Board in April 2021.

Professor Barton OAM is Scientia Professor of Radiation Oncology at UNSW Sydney. He has research interests in Health Services research and is a global leader in the benchmarking of cancer services. He is part of the leadership of the team developing one of the world's first MRI-guided linear accelerators. Professor Barton has worked for International Atomic Energy Agency on radiotherapy projects in Africa, Asia, and Latin America. Professor Barton chaired the National Adult Glioma Guidelines. He has a long track record of working with consumers on the design, execution and publication of research projects including the Ideal Curriculum in Oncology for Medical Students, publications in Lancet Oncology and the Medical Journal of Australia.

In 2007 he was awarded the Medal of the Order of Australia, for service to medicine, particularly radiation oncology, through a range of clinical, research, education, and professional development roles. In 2021 he received the Clinical Oncology Society of Australia Tom Reeve Award for Outstanding Contributions to Cancer Care.

James Butler

*Member of the Remuneration and Nomination Committee,
Chair of the Consumer Research Review Panel,
former Chair of the Relay For Life Steering Committee,
Co-Chair of the Aboriginal Advisory Committee*

Elected to the Board in December 2014, re-elected in December 2017, and re-elected in December 2020.

Mr Butler has been an active volunteer for Cancer Council NSW for 25 years, holding roles including Chair of the Hills Relay For Life Committee, and Chair of the Western Sydney Cancer Advocacy Network. He is a trained Cancer Council NSW advocate. As a two-time cancer survivor, he understands the need to influence decision-makers around key issues that have an impact on people affected by cancer.

Mr Butler is currently Chair of Cancer Council NSW's Consumer Research Review Panel. Mr Butler has also been a business owner for 25 years (now retired) and is an active consumer representative on cancer services committees in the Western Sydney Local Health District. Mr Butler was made an Officer of the Order of Australia in June 2022 for his service to people with cancer and his dedication to the work of Cancer Council NSW.

Nerida Dean

BEd Dip Ed (UNE)

*Member of the Remuneration and Nomination Committee,
Member of the Fundraising and Marketing Committee*

Appointed to the Board in October 2018, then elected to the Board in December 2018 and re-elected in December 2021.

Ms Dean brings a wealth of experience and a strong community perspective. She has spent the bulk of her working life as a secondary teacher and has served on several Boards at a local and regional level, including as the Deputy Chair Queanbeyan Local Health Committee for 14 years.

Ms Dean is currently a member of the Rotary Club of Mullumbimby and is involved with the build of the new Tweed Hospital. She has been involved with Cancer Council NSW for eight years, taking on numerous volunteer roles such as Community Speaker, MP Liaison, Relay for Life Committee member, Eat It To Beat It facilitator, Australia's Biggest morning tea host and Daffodil Day stall holder.

A/Professor Haryana Dhillon

BSc MA(Psych) PhD

*Member of the Governance Committee, Member of the
Cancer Research Committee*

Appointed to the Board in July 2019.

A/Professor Dhillon (BSc MA PhD) is an Associate Professor in Psycho-Oncology at the University of Sydney. She is a Director of the Centre for Medical Psychology & Evidence-based Decision-making, School of Psychology at the University of Sydney where she co-leads the Cancer Survivorship Research Group.

A/Professor Dhillon has more than 25 years' experience in cancer clinical research originally working with the NHMRC Clinical Trial Centre, the University of Sydney across a range of investigator-initiated cancer clinical trials. Over the past 15 years she has focused more on psycho-oncology and behavioural research.

A/Professor Dhillon was formerly a member of the Clinical Oncology Society of Australia Board and Chair of the Survivorship group of COSA. She is Chair of the Scientific Advisory Committee of the Psycho-Oncology Cooperative Research.

Peeyush Gupta AM

MBA (Finance)

*Member of the Investment Committee and Member of the IT
Steering Committee*

Appointed to the Board in August 2022.

Mr Gupta AM is the Chairman and non-executive Director on a range of commercial, public sector and not-for-profit boards, including as Chair of Charter Hall Long Wale REIT and Charter Hall Direct Property Management Ltd, and as a Director of National Australia Bank, SBS, Link Administration, Insurance and Care (NSW), Quintessence Labs, and Northern Territory Aboriginal Investment Corporation. This includes serving on various sub-committees of these Boards including in risk, remuneration, and investment. Mr Gupta was the co-founder and inaugural CEO of IPAC Securities, a wealth management firm providing financial advice and institutional portfolio management in Australia and internationally.

Mr Gupta holds a Master of Business Administration in Finance from the Australian Graduate School of Management, University of NSW, and is also an alumnus of Harvard and the London Business School. He was awarded a Member of the Order of Australia (AM) in January 2019 for significant service to business and the community through governance and philanthropic roles.

Carolyn Heise

BN, RN, PGDip Public Health (Leadership), MBA

*Chair of the Remuneration and Nomination Committee,
Member of the Aboriginal Advisory Committee*

Elected to the Board in December 2020.

Ms Heise is a dedicated registered nurse and health service leader. She is passionate about the nursing profession and the provision of high-quality health services to her community. Ms Heise's dynamic and varied career has included working as a registered nurse, managing district cancer services, public hospitals, and preventative health care services on the Mid North Coast of NSW. She holds additional post-graduate qualifications in Public Health and a Master of Business Administration.

Ms Heise has worked alongside Cancer Council in Regional NSW for many years and while in the Position of Nurse Manager for the Mid North Coast Cancer Institute in 2017, she actively participated in fundraising events such as Australia's Biggest Morning Tea and as a contestant in Coffs Coast Dancing with the Stars.

In 2019 while working as the Director of Nursing, Midwifery and In-Patient Services at Coffs Harbour Base Hospital, Ms Heise was diagnosed with cancer. As such, she has a unique perspective on the patient journey – both as a senior health service manager and as a survivor of cancer.

Dr John Laker AO

**BEd (Hons 1) (Syd), MSc (Econ) PhD (London),
HonDSc (Syd)**

Chair of the Board from 8 December 2022. Chair of the Governance Committee, Chair of the Audit and Risk Committee until 7 December 2022, Cancer Council NSW representative on the Cancer Council Australia Board

Elected to the Board in December 2014, re-elected in December 2017, and re-elected in December 2020.

Dr Laker was Chairman of the Australian Prudential Regulation Authority (APRA), the regulator of the Australian financial services industry, from 2003 to 2014. An economist by training, Dr Laker had an extensive career in the Reserve Bank of Australia, both in Australia and London, before his appointment to APRA. He has also worked in the Commonwealth Treasury and the International Monetary Fund (IMF).

Currently, Dr Laker is Chairman of ING Bank Australia and Deputy Chancellor and member of the Council of the University of Technology Sydney. He was also Chairman of The Banking and Finance Oath Limited until August 2021. He is a member of the Consultative Panel of the Australian Securities and Investments Commission (ASIC) and an External Expert for the IMF, participating in a number of reviews of major banking systems. He also lectures at The University of Sydney. Dr Laker was made an Officer of the Order of Australia in 2008 and has won other professional awards for his services to the regulation of the Australian financial system.

Dr Jo Mitchell

BSc, Post Grad Dip Nut & Diet, MPH, DrPH, GAICD

Member of the Audit and Risk Committee, Member of the Remuneration and Nomination Committee, Cancer Council NSW representative on the Cancer Council Australia Board

Appointed to the Board in November 2019.

Dr Mitchell has worked in preventive health for more than 30 years. Her career has included senior public sector executive experience, most recently as policy lead for population health in NSW. This portfolio covered a range of complex and contested policy issues including drug and alcohol, HIV, and sexually transmitted infections, overweight and obesity, tobacco control and viral hepatitis.

In 2018 Dr Mitchell was awarded the Public Service Medal for her contribution to population health policy in NSW.

She is currently an independent consultant and senior advisor to The Australian Prevention Partnership Centre. Dr Mitchell has degrees in science, nutrition, and public health.

Michael Morgan**BSc (Arch) BArch FRAIA**

Chair of the Investment Committee, Chair of the Audit and Risk Committee from 1 May 2022, Member of the Fundraising and Marketing Committee

Appointed to the Board in November 2020 and then elected in December 2020.

Mr Morgan is a registered architect and a director of nettletontribe where he has worked since 1979. He served as Managing Director for 26 years until commencing a leadership transition process in 2016.

Mr Morgan has been a member of the POSH Committee and an active supporter of Cancer Council NSW since 2003 and is the current Chair of the POSH Committee, a position he took up in late 2018.

He is also the Chairman of the Board of St Aloysius' College Ltd, Chairman of the Advisory Board for MacKillop Grange Retirement Village and a Director of Catholic Healthcare Ltd and The Cardoner Project Limited (a young adult ministry of the Jesuit Province of Australia).

Mark Phillips**BCom (Hons), MCom, FAICD**

Chair of the Board until 7 December 2021, Chair of the Audit and Risk Committee until retirement on 30 April 2022

Appointed to the Board in April 2013 and re-appointed in April 2016 and April 2019. Mr Phillips retired from the Board in April 2022.

Mr Phillips began his professional career in banking. In a 20-year period with the Commonwealth Bank of Australia, he was instrumental in the development of a range of new business divisions. Subsequently, Mr Phillips spent 10 years as the Chief Executive Officer of companies listed on the Australian Securities Exchange, and then became an adviser to, and director of, a number of businesses and not-for-profit organisations. He is currently Chief Executive Officer of CatholicCare Sydney, Co-chair of End Street Sleeping Collaboration Ltd, and non-executive director of Access Programs Australia Ltd.

Directors' benefit

No Director of Cancer Council NSW has received, or has become entitled to receive, a benefit in respect of their role as a Director.

Board and committee meeting attendance

	Full meetings of Directors		Audit and Risk Committee		Investment Committee		Governance Committee		Remuneration and Nomination Committee		Fundraising and Marketing Committee		Cancer Research Committee	
	A	B	A	B	A	B	A	B	A	B	A	B	A	B
N Adams	6	6	*	*	*	*	*	*	*	*	7	7	*	*
M Barton	6	6	*	*	*	*	*	*	*	*	*	*	3	3
J Butler	6	6	*	*	*	*	*	*	4	4	*	*	*	*
N Dean	6	6	*	*	*	*	*	*	4	4	7	7	*	*
H Dhillon	5	6	*	*	*	*	4	4	*	*	*	*	1	3
C Heise	6	6	*	*	*	*	*	*	4	4	*	*	*	*
J Laker	6	6	3	3	*	*	4	4	*	*	*	*	*	*
J Mitchell	5	6	5	6	*	*	*	*	*	*	*	*	*	*
M Morgan	6	6	3	3	4	4	*	*	*	*	6	7	*	*
M Phillips¹	6	6	2	2	*	*	*	*	*	*	*	*	*	*

A = Number of meetings attended

B = Number of meetings held during the time the Director held office or was a member of the Committee during the year.

* = Not a member of the relevant Committee

¹ Mark Phillips retired 30 April 2022

Review of financial operations and results

CCNSW achieved an operating surplus of \$3,270,000 for the fiscal year (2021: deficit of \$5,289,000). This improvement in year-on-year operating performance occurred despite the coronavirus pandemic having a residual impact on our overall fundraising revenues.

The results of CCNSW's net operations in the fiscal year is a deficit of \$11,892,000 (2021: surplus of \$5,830,000). This deficit resulted from the unrealised decrease in fair value of our investment portfolio, caused by the downturn in financial markets in the latter part of the year.

Fundraising income (excluding Gifts in Wills) of \$39,727,000 was 5.6% higher than the previous fiscal year, however still 14% below pre-pandemic levels. Gifts in Wills of \$14,035,000 was marginally under the average of prior years, mainly due to the timing finalisation of some large estates and is expected to return to long-term averages in future years. Distributions from our financial assets delivered strong returns, however this was offset by a downturn in financial markets in the second half of the fiscal year. CCNSW continues to provide support to the NSW community impacted by cancer, and it is pleasing to see that this support once again grew in the current fiscal year.

Reserves at the beginning of the fiscal year were more than \$100m, however due to the downturn in financial markets, reserves have marginally reduced to just below \$100m. These reserves, along with management's continued focus on growing revenue, make us confident in our ability to support the community and at the same time improve the financial stability of CCNSW.

Members' liability

CCNSW is incorporated under the Corporations Act 2001 (Cth) and is a public company limited by guarantee. If CCNSW is wound up, the constitution states that each member of CCNSW is required to contribute a maximum of \$2 each towards meeting any liabilities of CCNSW. As at 30 June 2022, the number of members was 94 (2021: 101).



Dr John Laker
Director

Sydney
25 October 2022



Michael Morgan
Director

Sydney
25 October 2022

DECLARATION OF INDEPENDENCE BY NAME OF LEAH RUSSELL TO THE DIRECTORS OF CANCER COUNCIL NSW

As lead auditor of Cancer Council NSW for the year ended 30 June 2022, I declare that, to the best of my knowledge and belief, there have been:

1. No contraventions of the auditor independence requirements of section 60-40 of the *Australian Charities and Not-for-profit Commission Act 2012* in relation to the audit; and
2. No contraventions of any applicable code of professional conduct in relation to the audit.

This declaration is in respect of Cancer Council NSW and the entities it controlled during the period.



Leah Russell
Director

BDO Audit Pty Ltd
Sydney
25 October 2022

Statement of profit or loss and other comprehensive income

For the year ended 30 June 2022

	Notes	2022 \$'000	2021 \$'000
Revenue			
Fundraising	3	53,761	58,262
Grants and government support	5	6,824	10,592
Interest and investment		11,036	6,070
Sale of sun protection products (retail)		5,191	5,173
Other (contributions from other Cancer Councils, publications and joint ventures)		1,034	1,108
Total revenue		77,846	81,205
Increase in fair value of investment property		-	-
Total income	4	77,846	81,205
Expenses			
Fundraising	3	23,144	21,667
Research - Grant contracts reissued	6		17,847
Research	3,6	18,239	16,876
Community engagement	3	8,758	9,112
Cancer information and support services	3	9,267	8,146
Sale of sun protection products (retail)	3	5,044	4,860
Advocacy and cancer prevention	3	5,635	4,023
Administration		2,126	2,450
Marketing and communications	3	2,363	1,513
Total expenses		74,576	86,494
Operating surplus/(deficit)		3,270	(5,289)
Income tax expense	2 (c)	-	-
Increase/(decrease) in investments at fair value	9 (b)	(15,162)	11,119
Fair value adjustment to investment property		-	-
Surplus/(deficit) for the year		(11,892)	5,830
Other comprehensive income			
Items that will not be reclassified subsequently to surplus or deficit:			
Revaluation of land and buildings	11	1,118	20,341
Total other comprehensive income for the year		1,118	20,341
Net result for the year		(10,774)	26,171

The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes.

Statement of financial position

As at 30 June 2022

	Notes	2022 \$'000	2021 \$'000
Assets			
Current assets			
Trade and other receivables	7	11,651	13,318
Cash and cash equivalents	8	8,632	27,110
Financial assets	9	21,218	5,111
Held for sale assets	10	-	1,155
Inventories		550	447
Total current assets		42,051	47,141
Non-current assets			
Financial assets	9	79,770	85,576
Property, plant and equipment	11	50,597	50,679
Intangible assets	12	5,447	5,524
Right of use assets	13	1,194	1,712
Investment properties		-	-
Total non-current assets		137,008	143,491
TOTAL ASSETS		179,059	190,632
Liabilities			
Current liabilities			
Trade and other payables	14	8,637	10,085
Provision for grants	15	7,374	7,531
Contract Liability		3,878	527
Lease liabilities	16	929	960
Provisions – employee benefits	17	4,063	3,735
Total current liabilities		24,881	22,838
Non-current liabilities			
Provision for grants	15	7,446	9,998
Lease liabilities	16	318	800
Provisions – employee benefits	17	1,055	863
Total non-current liabilities		8,819	11,661
TOTAL LIABILITIES		33,700	34,499
NET ASSETS		145,359	156,133
Equity			
Accumulated funds		84,299	83,488
Asset revaluation reserve		46,309	45,191
Investments at fair value reserve		5,558	20,720
Restricted funds reserve		5,611	4,262
Grant income reserve		3,582	2,472
TOTAL EQUITY		145,359	156,133

The above statement of financial position should be read in conjunction with the accompanying notes.

Statement of changes in equity

For the year ended 30 June 2022

	Accumulated funds \$'000	Asset revaluation reserve \$'000	Investments at fair value reserve \$'000	Restricted funds reserve \$'000	Grant income reserve \$'000	Total equity \$'000
Opening balance as at 1 July 2020	89,047	24,850	9,601	4,018	2,468	129,984
Transfer to/(from) reserves	(11,367)	-	11,119	244	4	-
Casuarina Lodge	(22)	-	-	-	-	(22)
Surplus/(deficit) for the year	5,830	-	-	-	-	5,830
Other comprehensive income for the year	-	20,341	-	-	-	20,341
Net result for the year	5,830	20,341	-	-	-	26,171
Closing balance as at 30 June 2021	83,488	45,191	20,720	4,262	2,472	156,133
Opening balance as at 1 July 2021	83,488	45,191	20,720	4,262	2,472	156,133
Transfer to/(from) reserves	12,703	-	(15,162)	1,349	1,110	(0)
Surplus/(deficit) for the year	(11,892)	-	-	-	-	(11,892)
Other comprehensive income for the year	-	1,118	-	-	-	1,118
Net result for the year	(11,892)	1,118	-	-	-	(10,774)
Closing balance as at 30 June 2022	84,299	46,309	5,558	5,611	3,582	145,359

The above statement of changes in funds should be read in conjunction with the accompanying notes.

Nature and purpose of reserves

Accumulated funds

Accumulation of funds over time as a net result of past surpluses and deficits.

Asset revaluation reserve

The asset revaluation reserve is used to record increments and decrements on the revaluation of CCNSW land and buildings, as described in note 11.

Investments at fair value reserve

The investments at fair value reserve is used to record changes in the fair value of financial assets classified as investments at fair value through profit and loss, as described in note 9 (b).

Restricted funds reserve

The restricted funds reserve relates to bequests and donations received by CCNSW with a purpose specified in the bequest or by the donors. These funds are held in the restricted funds reserve until spent appropriately.

Grant income reserve

The grant income reserve relates to grant monies received but not yet spent. These funds are held in reserve until spent appropriately in line with the conditions of the funding agreement.

Statement of cash flows

For the year ended 30 June 2022

	2022 \$'000	2021 \$'000
Cash flows from operating activities		
Receipts from supporters and funding sources (inclusive of GST)	64,640	60,432
Receipts from grant and government funding	10,507	11,337
Dividends, franking credits and interest received	529	927
Receipts from joint operations	-	1,336
Lease interest	(56)	(56)
Payments to suppliers and employees (inclusive of GST)	(75,206)	(61,488)
Net cash inflow/(outflow) from operating activities	414	12,488
Cash flows from investing activities		
Proceeds from sale of property, plant and equipment	87	146
Proceeds from sale of held for sale assets	1,176	4,152
Proceeds from sale of/(payment for) financial assets	(17,107)	(10,000)
Payments for purchase of intangible assets	(1,341)	(1,288)
Payments for purchase of property, plant and equipment	(544)	(294)
Net cash inflow/(outflow) from investing activities	(17,729)	(7,284)
Cash flows from financing activities		
Payments for principle portion of lease liabilities	(1,163)	(1,120)
Net cash outflow from financing activities	(1,163)	(1,120)
Net increase in cash and cash equivalents	(18,478)	4,084
Cash and cash equivalents at beginning of year	27,110	23,026
Cash and cash equivalents at end of year	8,632	27,110

The above statement of cash flows should be read in conjunction with the accompanying notes.

Notes to the financial statements

For the year ended 30 June 2022

1. Introduction

This financial report covers Cancer Council NSW (CCNSW) as an individual entity for the year ended 30 June 2022. The financial report is presented in Australian dollars, which is the company's functional and presentational currency.

CCNSW is a not-for-profit unlisted public company limited by guarantee, incorporated and domiciled in Australia. Its registered office and principal place of business is:

The Cancer Council NSW
153 Dowling Street
Woolloomooloo NSW 2011

A description of the nature of CCNSW's operations and its principal activities is included on page 10.

The financial report was authorised for issue by the Directors on 25 October 2022. The Directors have the power to amend and reissue this financial report.

2. Significant accounting policies

The principal accounting policies adopted in the preparation of this financial report are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

(a) Basis of preparation

These general-purpose financial statements have been prepared on a going concern basis and in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (AASB), NSW legislation (the *Charitable Fundraising Act 1991* (NSW) and associated regulations), and the *Australian Charities and Not-for-profits Commission Act 2012* (Cth), as appropriate for not-for-profit oriented entities.

CCNSW has applied Simplified Disclosure Requirements as set out in AASB 1060: General Purpose Financial Statements – Simplified Disclosures for For-Profit and Not for Profit Entities. This application was approved by the Board of CCNSW.

CCNSW is a not-for-profit organisation and as such the term 'profit' is not applicable and the term 'surplus' is used where required.

Historical cost convention

These financial statements have been prepared under the historical cost convention, as modified by the revaluation of financial assets and liabilities, certain classes of property, plant and equipment, and investment property.

(b) Change in accounting policy

CCNSW has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (AASB) that are mandatory for the current reporting period.

The following Accounting Standards and Interpretations have been adopted by CCNSW for the reporting period ended 30 June 2022.

(c) Income tax

CCNSW is exempt from income tax within the terms of Subdivision 50-5 of the *Income Tax Assessment Act 1997* (Cth).

(d) Goods and services tax (GST)

Revenues, expenses and assets are recognised net of the amount of GST, unless the amount of GST incurred is not recoverable from the Australian Taxation Office (ATO). In this case, it is recognised as part of the cost of acquisition of the asset or as part of the expense.

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST receivable from or payable to the ATO is included with other receivables or payables in the statement of financial position.

(e) Public company limited by guarantee

In the event of CCNSW being wound up, the liability of each member is limited to an amount not exceeding \$2.

(f) Rounding off

CCNSW is of a kind referred to in Legislative Instrument 2016/191, issued by the Australian Securities and Investments Commission, relating to the 'rounding off' of amounts in the financial report. Amounts in the financial report have been rounded off in accordance with the class order to the nearest thousand dollars.

(g) Critical estimates and judgements

The preparation of financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying CCNSW's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, can be found in the following notes to the financial statements:

	Note
Financial assets	9
Useful life of assets	11
Employee benefits	17

(i) Financial assets at fair value through profit or loss

CCNSW holds an investment in shares classified as financial assets at fair value through profit or loss. As at 1 July 2018, in adopting AASB 9: Financial Instruments CCNSW has made an irrevocable election on initial recognition to present gains and losses on investments in equity instruments that are not held for trading through profit or loss.

(ii) Estimation of useful lives of assets

CCNSW determines the estimated useful lives and related depreciation and amortisation charges for its property, plant and equipment, and finite life intangible assets. The useful lives could change significantly as a result of technical innovations or some other event. The depreciation and

Notes to the financial statements continued

amortisation charge will increase where the useful lives are less than previously estimated lives, or where technically obsolete or non-strategic assets that have been abandoned or sold will be written off or written down.

iii) Long service leave provision

The liability for long service leave is recognised and measured at the present value of the estimated future cash flows to be made in respect of all employees at the reporting date. In determining the present value of the liability, estimates of attrition rates and pay increases through promotion and inflation have been taken into account.

iv) Determining whether a grant contains enforceable and sufficiently specific obligations

The interaction between AASB 15 and AASB 1058 requires management to assess whether the government grants and other funding received need to be accounted for under AASB 15 or AASB 1058. Key to this assessment is whether the government funding and other funding agreements contain:

- a contract with a customer that creates 'enforceable' rights and obligations, and
- the contract includes 'sufficiently specific' performance obligations.

Critical judgement was applied by management in assessing whether a promise is 'sufficiently specific'. Taking into account all facts and circumstances and any conditions specified in the arrangement (whether explicit or implicit) regarding the promised goods or services, including conditions regarding:

- the nature or type of the goods and services
- the cost or value of the goods and services
- the quantity of the goods and services
- the period over which the goods and services must be transferred.

3. Fundraising

	2022 \$'000	2021 \$'000
(a) Fundraising income		
Gifts in wills	14,035	20,653
Regular giving, appeals and donations	18,137	18,567
Campaigns	13,193	16,257
Philanthropy	8,396	2,785
	53,761	58,262
Fundraising revenue is recognised under AASB 1058 when received or receivable.		
(b) Fundraising activities		
The below information is furnished under the <i>Charitable Fundraising Act 1991</i> (NSW) and NSW Fair Trading Fundraising Authority Conditions.		
Gross proceeds from fundraising activities (including gifts in wills)	53,761	58,262
Total cost of fundraising appeals	(23,144)	(21,667)
Net surplus from fundraising appeals	30,617	36,595
(c) Mission expenditure		
Research	18,239	16,876
Community engagement	8,758	9,112
Cancer information and support services	9,267	8,146
Sale of sun protection products (retail)	5,044	4,860
Advocacy and cancer prevention	5,635	4,023
Direct mission support - Marketing and communications*	2,363	1,513
Total mission expenditure	49,306	44,530
Mission spend as a percentage of total expenses	66%	65%
Mission spend as a percentage of net surplus from fundraising	161%	122%

*Items from these categories which are directly related to mission have been reallocated to Direct mission support.

Notes to the financial statements continued

4. Revenue and Other income

	2022 \$'000	2021 \$'000
Revenue		
Sale of Retail Products recognised at a point in time	5,191	5,173
Provision of services rendered at a point in time	1,034	1,108
Non government grants recognised at a point in time	2,353	1,680
Government Grants recognised at a point in time		
NSW Department of Communities and Justice	143	
Cancer Institute NSW	248	473
Australian Government National Health and Medical Research Council	648	1,034
Australian Government Department of Health	666	932
NSW Ministry of Health		23
	10,283	10,423
Non government grants recognised over time	397	
Government Grants recognised over time		
Australian Department of Industry, Science, Energy and Resources	70	
Australian Government Department of Health	1,447	1,085
Cancer Institute NSW	347	18
NSW Ministry of Health	105	120
Total Revenue	12,649	11,646
Other income		
Fundraising	53,761	58,262
NSW Government - JobSaver	400	
Commonwealth Government - JobKeeper		5,227
Interest and Investment	11,036	6,070
Total Other Income	65,197	69,559
Total Revenue and other Income	77,846	81,205

5. Grants and government support

	Opening balance 1 July 2021 \$'000	Receipts 2022 \$'000	Payments 2022 \$'000	Closing balance 30 June 2022 \$'000
Cancer research grants	2,224	4,260	(3,940)	2,544
Community support grants	34	1,183	(992)	225
Cancer prevention grants	214	981	(382)	813
Total grants	2,472	6,424	(5,314)	3,582
JobKeeper receipts		400		
Total grants and government support		6,824		

Grants from the government and other organisations are recognised at their fair value through profit and loss where the sufficiently specific performance obligations of the grant have been met. Where those obligations have not been met for the year revenue is deferred until those obligations are satisfied.

Where a grant is received without sufficiently specific performance obligations the revenue is recognised upon receipt through profit and loss.

Notes to the financial statements continued

6. Research expenditure

	2022 \$'000	2021 \$'000
Research – Grant contracts reissued	–	17,847
Research	18,239	16,876
	18,239	34,723

As at 30 June 2022 Cancer Council has recognised all grant commitments on the Statement of financial position. These liabilities have been split as per accounting guidelines to their current and non-current portions.

Grant agreements were updated via variation letters issued prior to June 30 2021 resulting in the creation of constructive obligations on behalf of Cancer Council and thus the addition of grant liabilities on the statement of financial position.

The full impact of this change has been taken up at June 2021 with no impact on prior year numbers.

7. Trade and other receivables

	2022 \$'000	2021 \$'000
Trade receivables	8,066	9,329
Provision for impairment of trade receivables	(2)	(2)
Other receivables	1,099	855
National fundraising campaigns due from Cancer Council Australia	2,488	3,136
	11,651	13,318

Trade receivables are initially recognised at fair value, and subsequently measured at amortised cost. Trade receivables are generally due for settlement within 30 days.

A provision is made for doubtful debts when there is evidence that those debts may not be collected. Bad debts are written off when identified.

8. Cash and cash equivalents

	2022 \$'000	2021 \$'000
Cash on hand and at bank	8,632	27,110
	8,632	27,110

For statement of cash flow presentation purposes, cash and cash equivalents include cash on hand; deposits held at call with financial institutions; and other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and that are subject to an insignificant risk of change in values.

Notes to the financial statements continued

9. Financial assets

	2022 \$'000	2021 \$'000
Current assets – Financial assets at amortised cost		
Term deposits	21,000	5,000
Financial assets at amortised cost	218	111
	21,218	5,111
Non-current assets – Investments at fair value through profit or loss		
(a) Investments at the end of the financial year were as follows:		
Australian shares (tax exempt)	25,671	28,400
Overseas shares (unhedged)	16,473	20,397
Cash fund	8,484	8,478
Australian sovereign bonds	7,130	8,001
Global credit fund	6,342	7,292
Australian small companies fund	6,893	8,266
Overseas sovereign bonds	2,415	2,611
Emerging markets fund	2,480	2,131
International Property	1,762	-
Global Infrastructure fund	2,120	-
	79,770	85,576
Changes in the fair value of investments are recorded in equity and disclosed through profit or loss.		
(b) Movement in investments		
Opening balance 1 July	85,576	67,702
Additions	13,356	7,772
Increase/(decrease) in fair value of managed funds	(15,162)	11,119
Disposals	(4,000)	(1,017)
Closing balance 30 June	79,770	85,576

Classification of financial assets

CCNSW classifies its financial assets in the following categories: 'investments at fair value through profit or loss', and 'financial assets at amortised cost'. The classification depends on the purpose for which the financial assets were acquired. Management determines the classification of CCNSW's financial assets at initial recognition:

(i) Investments at fair value through profit or loss

At initial recognition, CCNSW may make an irrevocable election (on an instrument-by-instrument basis) to recognise the change in fair value of investments in equity instruments through profit or loss. This election is permitted for equity instruments that are not held for trading purposes.

(ii) Financial assets at amortised cost

Financial assets at amortised cost are recognised initially at fair value and subsequently measured at amortised cost using the effective interest rate method, less provision for impairment.

These instruments are initially recognised at fair value plus transaction costs. Subsequent to initial recognition, they are measured at fair value and changes therein are

recognised through profit or loss and presented within equity in the investments at fair value reserve. When an instrument is derecognised, the cumulative gain or loss is transferred directly to retained earnings and is not recognised in profit or loss.

Dividends or other distributions received from these investments are still recognised in profit or loss as part of interest and investment income.

Recognition and derecognition

Regular purchases and sales of financial assets are recognised on trade date – the date on which CCNSW commits to purchase or sell the asset. Investments are initially recognised at fair value plus transaction costs for all financial assets not carried at fair value through profit or loss. Financial assets are derecognised when the rights to receive cash flows from the financial assets have expired or have been transferred, and CCNSW has transferred substantially all the risks and rewards of ownership.

Notes to the financial statements continued

10. Held for sale assets

	2022 \$'000	2021 \$'000
Building	-	1,155
	-	1,155

The two units transferred to held-for-sale in 2021, were settled in July 2021 and August 2021.

11. Property, plant and equipment

	Buildings*	Freehold land*	Motor vehicles	Office furniture and equipment	Leasehold improvements	Total
	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000
Year ended 30 June 2022						
Opening net book amount	28,328	20,190	887	1,198	76	50,679
Additions	-	-	73	172	299	544
Revaluation increment	808	310	-	-	-	1,118
Disposals	-	-	(25)	-	-	(25)
Depreciation expense	(772)	-	(328)	(527)	(92)	(1,719)
Closing net book amount	28,364	20,500	607	843	283	50,597
At 30 June 2022						
Cost or fair value*	30,056	20,500	1,830	7,500	2,276	62,162
Accumulated depreciation	(1,692)	-	(1,223)	(6,657)	(1,993)	(11,565)
Net book amount	28,364	20,500	607	843	283	50,597

* Valued at Fair Value

Valuations of freehold land and buildings

All property, plant and equipment categories are valued at cost, with the exception of land and buildings. The valuation basis of land and buildings is fair value. Building valuations were conducted as at 30 June 2021, with revaluations based on independent assessments by members of the Australian Property Institute. The revaluation increment was credited to the asset revaluation reserve in accumulated funds.

Any accumulated depreciation at the date of revaluation is eliminated against the gross carrying amount of the asset, and the net amount is restated to the revalued amount of the asset. All other property, plant and equipment are stated at historical cost less depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

Land is not depreciated. Depreciation on other assets is calculated using the straight-line method to allocate their cost or revalued amounts, net of their residual values, over their estimated useful lives, as follows:

- buildings 25 to 40 years
- leasehold improvements 2 to 5 years
- office furniture and equipment 3 to 10 years
- motor vehicles 5 years

The asset residual values and useful lives are reviewed, and adjusted if appropriate, at each reporting period. An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount. Gains and losses are determined by comparing proceeds with carrying amount. These are included in the statement of profit or loss and other comprehensive income.

Notes to the financial statements continued

12. Intangible assets

	Computer software \$'000	Internally generated intangible assets \$'000	Total \$'000
Year ended 30 June 2022			
Opening net book amount	58	5,466	5,524
Additions	-	1,341	1,341
Disposals	-	-	-
Impairment recognition	-	-	-
Amortisation	(17)	(1,401)	(1,418)
Closing net book amount	41	5,406	5,447
At 30 June 2022			
Cost or fair value	1,029	12,122	13,151
Accumulated amortisation	(988)	(5,350)	(6,338)
Intangible impairment	-	(1,366)	(1,366)
Net book amount	41	5,406	5,447

Finite intangible assets include acquired or developed software, capitalised on the basis of the costs incurred to acquire and install the software. Subsequent software expenditure is expensed as incurred.

Finite intangible assets are accounted for using the cost model, whereby capitalised costs are amortised on a straight-line basis over their estimated useful lives (between 3 to 10 years). Residual values and useful lives are reviewed at each reporting date.

CCNSW continues to invest in technology to improve how it engages with the community, simplify its working environment and help it work more effectively.

At financial year end intangibles were reviewed with the above impairment calculated as the expended cost on software development no longer having future benefit to CCNSW.

13. Right-of-use assets

	2022 \$'000	2021 \$'000
Opening balance 1 July	1,712	1,311
Additions	548	1499
Less: accumulated depreciation	(1,066)	(1,098)
Closing balance at 30 June	1,194	1,712

Right of use assets are CCNSW's right to use leased assets over the life of their leases and have come into effect from 1 July 2019 due to the application of AASB 16.

Included in surplus/(deficit) for the year are \$1,065,715 (2021: \$1,098,367) of depreciation of right-of-use assets and \$50,202 (2021: \$56,386) of finance cost on lease liabilities. Expenses relating to short-term leases included in administrative expense in the profit or loss for the period were \$274,011 (2021: \$287,848). The total cash outflow for leases for the year was \$1,104,815 (2021: \$1,119,747).

Notes to the financial statements continued

14. Trade and other payables

	2022 \$'000	2021 \$'000
Trade creditors and accruals	6,766	8,688
Cancer Council Australia membership fees	1,630	1,060
Other current payables	241	337
	8,637	10,085

These amounts represent liabilities for goods and services provided to CCNSW prior to the end of the financial year and that were unpaid as at the reporting date. These amounts are unsecured and are paid within the suppliers' terms, usually 30 days. These amounts are unsecured and are paid within the suppliers' terms, usually 30 days.

15. Provision for grants

	2022 \$'000	2021 \$'000
Current grant provision	7,374	7,531
Non-current grant provision	7,446	9,998
Total grant liability	14,820	17,529

A provision is recognised when Cancer Council NSW has a present legal or constructive obligation as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation and the amount can be reliably measured.

Liabilities relating to research grants are provided for in order to recognise Cancer Council's obligation to pay grants to external agencies in accordance with funding agreements that commit Cancer Council NSW to pay these funds per agreed milestones.

16. Lease liabilities

	2022 \$'000	2021 \$'000
Current lease liability	929	960
Non-current lease liability	318	800
Total lease liability	1,247	1,760

The above lease liabilities represent the present value of the remaining lease payments, discounted using the appropriate incremental borrowing rate.

Future Lease payments are due as follows:

Within one year	929	960
One to five years	318	800
More than five years		
	1,247	1,760

Notes to the financial statements continued

17. Employee benefits

	2022 \$'000	2021 \$'000
(a) Employee benefits provisions – Current		
Annual leave	2,996	2,721
Long service leave	1,067	1,014
Current employee benefits	4,063	3,735
(b) Employee benefits provisions – Non-current		
Long service leave	1,055	863
Non-current employee benefits	1,055	863

Short-term employee benefits

Liabilities for wages and salaries, including non-monetary benefits, and leave expected to be settled within 12 months of the reporting date, are recognised in current liabilities, and are measured at the amounts expected to be paid when the liabilities are settled.

Other long-term employee benefits

The leave liabilities not expected to be settled within 12 months of the reporting date are recognised in non-current liabilities. The liability is measured as the present value of expected future payments to be made in respect of services provided by employees up to the reporting date, using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures, and periods of service. Expected future payments are discounted using market yields at the reporting date on national government bonds with terms to maturity and currency that match, as closely as possible, the estimated future cash outflows.

(c) Employee benefits expense

Employee benefits expense	39,134	35,557
----------------------------------	---------------	---------------

18. Key management personnel

	2022 \$	2021 \$
(a) Executive remuneration		
Executive (excluding Directors of the Board) remuneration expense	2,316,432	1,984,803

Directors of the Board are all volunteers, and receive no remuneration for their services.

(b) Transactions with Directors and key management personnel

During the financial year Dr John Laker and Jo Mitchell were unpaid Board members of both CCNSW and Cancer Council Australia (CCA). During the year CCNSW owed CCA \$2,172,557 for membership fees (as at 30 June 2022 \$1,629,418 were in payables (note 14)). CCNSW were due from CCA distributions for the NSW share of national fundraising campaigns of \$2,488,067 (as at 30 June 2022 \$2,488,067 remained in debtors (note 7)).

19. Remuneration of Auditors

	2022 \$	2021 \$
Audit of the Financial Statements	65,000	60,000

Notes to the financial statements *continued*

20. Contingent liabilities

CCNSW had no contingent liabilities as at 30 June 2022.

Bank Guarantees

CCNSW provided the following guarantees as at 30 June 2022.

- Bank guarantees in respect of property operating leases amounting to \$218K (2021: \$118,000).

21. Events after reporting period

CCNSW was not aware of any events that have occurred after reporting date that are of such significance that they need to be disclosed or recognised in the financial statements.

22. Interests in joint ventures

CCNSW has entered into a joint venture to provide accommodation for cancer patients and their relatives while receiving radiotherapy treatment in NSW: Lilier Lodge at Wagga Wagga.

CCNSW holds a 50% voting power in Lilier Lodge.

CCNSW holds a 50% ownership interest in the operations of Lilier Lodge and is entitled to a 50% share of their output.

CCNSW's 50% interest in Lilier Lodge's assets, liabilities, revenues and expenses was recognised in the financial statements as part of a joint operation.

23. New Accounting Standards

CCNSW has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (AASB) that are mandatory for the current reporting period.

Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of CCNSW.

END OF AUDITED FINANCIAL STATEMENTS

Directors' declaration

In the Directors' opinion:

- the attached financial statements and notes thereto comply with the Australian Charities and Not-for-profits Commission Act 2012 (Cth), Australian Accounting Standards-Simplified Disclosure Requirements, the Australian Charities and Not-for-profits Commission Regulations 2013 and other mandatory professional reporting requirements
- the attached financial statements and notes thereto give a true and fair view of the company's financial position as at 30 June 2022 and of its performance for the financial year ended on that date
- there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors and is signed for and on behalf of the Directors by:



Dr John Laker
Director

Sydney
25 October 2022



Michael Morgan
Director

Sydney
25 October 2022

Declaration by Chief Executive Officer in respect of fundraising appeals

I, Sarah Hosking, Chief Executive Officer of The Cancer Council NSW declare that in my opinion:

- a) the income statement gives a true and fair view of all income and expenditure of The Cancer Council NSW with respect to fundraising appeals
- b) the balance sheet gives a true and fair view of the state of affairs with respect to fundraising appeals
- c) the provisions of the Charitable Fundraising Act 1991 (NSW), the regulations under the Act and the conditions attached to the authority have been complied with
- d) the internal controls exercised by The Cancer Council NSW are appropriate and effective in accounting for all income received and applied by The Cancer Council NSW from any of its fundraising appeals.



Sarah Hosking
Chief Executive Officer

Sydney
25 October 2022

INDEPENDENT AUDITOR'S REPORT

To the members of The Cancer Council NSW

Report on the Audit of the Financial Report

Opinion

We have audited the financial report of The Cancer Council NSW (the registered entity), which comprises the statement of financial position as at 30 June 2022, the statement of profit or loss and other comprehensive income, the statement of changes in equity and the statement of cash flows for the year then ended, and notes to the financial report, including a summary of significant accounting policies, and the responsible entities' declaration.

In our opinion the accompanying financial report of The Cancer Council NSW, is in accordance with Division 60 of the *Australian Charities and Not-for-profits Commission Act 2012*, including:

- (i) Giving a true and fair view of the registered entity's financial position as at 30 June 2022 and of its financial performance for the year then ended; and
- (ii) Complying with Australian Accounting Standards – Simplified Disclosures and Division 60 of the *Australian Charities and Not-for-profits Commission Regulation 2013*.

Basis for opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the Financial Report* section of our report. We are independent of the registered entity in accordance with the auditor independence requirements of the *Australian Charities and Not-for-profits Commission Act 2012* (ACNC Act) and the ethical requirements of the Accounting Professional and Ethical Standards Board's *APES 110 Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other information

The responsible entities of the registered entity are responsible for the other information. The other information obtained at the date of this auditor's report is information included in the registered entity's annual report, but does not include the financial report and our auditor's report thereon.

Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon.



In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed on the other information obtained prior to the date of this auditor's report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of responsible entities for the Financial Report

The responsible entities of the registered entity are responsible for the preparation and fair presentation of the financial report in accordance with Australian Accounting Standards – Simplified Disclosures and the ACNC Act, and for such internal control as the responsible entities determine is necessary to enable the preparation of the financial report that is free from material misstatement, whether due to fraud or error.

In preparing the financial report, responsible entities are responsible for assessing the registered entity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the responsible entities either intends to liquidate the registered entity or to cease operations, or has no realistic alternative but to do so.

The responsible entities of the registered entity are responsible for overseeing the registered entity's financial reporting process.

Auditor's responsibilities for the audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website (<http://www.auasb.gov.au/Home.aspx>) at:

http://www.auasb.gov.au/auditors_responsibilities/ar4.pdf

This description forms part of our auditor's report.

BDO Audit Pty Ltd

BDO

Leah Russell

Leah Russell
Director

Sydney, 28 October 2022



**With your help, we are leading NSW
towards a cancer free future.**

- Volunteer with us
- Give regularly
- Host or join a fundraising event
- Campaign with us
- Visit one of our retail stores



**To find out more, visit
cancercouncil.com.au/get-involved**

Call **13 11 20** for information and support

This free and confidential service is staffed by experienced cancer professionals, who provide evidence-based information and support to people affected by cancer.

Contact us.

153 Dowling Street
Woolloomooloo NSW 2011
feedback@nswcc.org.au

 facebook.com/cancercouncilnsw

 [@ccnewsouthwales](https://twitter.com/ccnewsouthwales)

 youtube.com/cancercouncilnsw

 [@cancercouncilnsw](https://instagram.com/cancercouncilnsw)

 linkedin.com/company/cancer-council-nsw

13 11 20 cancercouncil.com.au



**Cancer
Council**
NSW